Company profile
Cumberland Pharmaceuticals Inc.
NASDAQ: CPIX · Healthcare · Drug Manufacturers - Specialty & Generic
#448 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
70BFH 65DQ 80GM 66SS 65
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), disclosure history · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$41.9M
Rev growth YoY (TTM)
+2.1%
Net income (FY)
-$2.8M
Employees
93
as of 2026-08-18
Market cap
$117.2M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$44.5M$44.5M2025
Net income-$2.8M-$2.8M2025
Operating income-$2.8M-$2.8M2025
Total assets$76.8M$76.8M2025
Liabilities$52.3M$52.3M2025
Equity$24.9M$24.9M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY24
FY25
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product75%
Product - Vibativ18%
Product - Other8%
By geography
Non-US100%
The read
What is Cumberland Pharmaceuticals Inc.’s revenue?
Cumberland Pharmaceuticals Inc. booked $44.5M in FY2025 revenue, growing 437% year over year — faster than 94% of Healthcare companies we track, at a -6.4% net margin.
Peers · Healthcare
PC Group, Inc.——Fennec Pharmaceuticals Inc.61CAquestive Therapeutics, Inc.47DNew York Health Care, Inc.——SANUWAVE Health Inc.74BHOOKIPA Pharma Inc.——Neighbors
Davidson →Key facts
CEOA. J. Kazimi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNashville, TN
ExchangeNASDAQ: CPIX
Employees93
IPO date2009-08-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.